Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 597-609

  El Kasmi, Karim C ^a   Pugliese, Steven C ^b   Riddle, Suzette R ^b   Poth, Jens M ^b   Anderson, Aimee L ^a   Frid, Maria G ^b   Li, Min ^b   Pullamsetti, Soni S ^c   Savai, Rajkumar ^c   Nagel, Maria A ^b   Fini, Mehdi A ^b   Graham, Brian B ^b   Tuder, Rubin M ^b   Friedman, Jacob E ^b   Eltzschig, Holger K ^b   Sokol, Ronald J ^a   Stenmark, Kurt R ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE PIM 1; STAT1 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR;

ADVENTITIAL FIBROBLAST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATTLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MACROPHAGE ACTIVATION; MONOCYTE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; CATTLE; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; HUMANS; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; INFLAMMATION; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; RATS, INBRED WKY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84904267310     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303048     Document Type: Article

References (71)

1. Morrell, N. W., S. L. Archer, A. Defelice, S. Evans, M. Fiszman, T. Martin, M. Saulnier, M. Rabinovitch, R. Schermuly, D. Stewart, et al. 2013. Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm. Circ. 3: 226-244.
2. Price, L. C., S. J. Wort, F. Perros, P. Dorfmüller, A. Huertas, D. Montani, S. Cohen-Kaminsky, and M. Humbert. 2012. Inflammation in pulmonary arterial hypertension. Chest 141: 210-221.
3. Savai, R., S. S. Pullamsetti, J. Kolbe, E. Bieniek, R. Voswinckel, L. Fink, A. Scheed, C. Ritter, B. K. Dahal, A. Vater, et al. 2012. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186: 897-908.
4. Stacher, E., B. B. Graham, J. M. Hunt, A. Gandjeva, S. D. Groshong, V. V. McLaughlin, M. Jessup, W. E. Grizzle, M. A. Aldred, C. D. Cool, and R. M. Tuder. 2012. Modern age pathology of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186: 261-272.
5. Stenmark, K. R., B. Meyrick, N. Galie, W. J. Mooi, and I. F. McMurtry. 2009. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L1013-L1032.
6. Tuder, R. M., and N. F. Voelkel. 1998. Pulmonary hypertension and inflammation. J. Lab. Clin. Med. 132: 16-24. (Pubitemid 28329606)
7. Tuder, R. M., S. L. Archer, P. Dorfmüller, S. C. Erzurum, C. Guignabert, E. Michelakis, M. Rabinovitch, R. Schermuly, K. R. Stenmark, and N. W. Morrell. 2013. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J. Am. Coll. Cardiol. 62(25, Suppl): D4-D12.
8. Frid, M. G., J. A. Brunetti, D. L. Burke, T. C. Carpenter, N. J. Davie, J. T. Reeves, M. T. Roedersheimer, N. van Rooijen, and K. R. Stenmark. 2006. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am. J. Pathol. 168: 659-669. (Pubitemid 43271163)
9. Hassoun, P. M., L. Mouthon, J. A. Barberà, S. Eddahibi, S. C. Flores, F. Grimminger, P. L. Jones, M. L. Maitland, E. D. Michelakis, N. W. Morrell, et al. 2009. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54(1, Suppl.): S10-S19.
10. Stenmark, K. R., M. G. Frid, M. Yeager, M. Li, S. Riddle, T. McKinsey, and K. C. El Kasmi. 2012. Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change. Pulm. Circ. 2: 3-14.
11. Stenmark, K. R., E. Nozik-Grayck, E. Gerasimovskaya, A. Anwar, M. Li, S. Riddle, and M. Frid. 2011. The adventitia: Essential role in pulmonary vascular remodeling. Compr. Physiol. 1: 141-161.
12. Stenmark, K. R., M. E. Yeager, K. C. El Kasmi, E. Nozik-Grayck, E. V. Gerasimovskaya, M. Li, S. R. Riddle, and M. G. Frid. 2013. The adventitia: essential regulator of vascular wall structure and function. Annu. Rev. Physiol. 75: 23-47.
13. Anwar, A., M. Li, M. G. Frid, B. Kumar, E. V. Gerasimovskaya, S. R. Riddle, B. A. McKeon, R. Thukaram, B. O. Meyrick, M. A. Fini, and K. R. Stenmark. 2012. Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 303: L1-L11.
14. Das, M., N. Burns, S. J. Wilson, W. M. Zawada, and K. R. Stenmark. 2008. Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia. Cardiovasc. Res. 78: 440-448. (Pubitemid 351769755)
15. Panzhinskiy, E., W. M. Zawada, K. R. Stenmark, and M. Das. 2012. Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGFβ receptor-JNK1 signalling. Cardiovasc. Res. 95: 356-365.
16. Wang, D., H. Zhang, M. Li, M. G. Frid, A. R. Flockton, B. A. McKeon, M. E. Yeager, M. A. Fini, N. W. Morrell, S. S. Pullamsetti, et al. 2014. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ. Res. 114: 67-78.
17. Li, M., S. R. Riddle, M. G. Frid, K. C. El Kasmi, T. A. McKinsey, R. J. Sokol, D. Strassheim, B. Meyrick, M. E. Yeager, A. R. Flockton, et al. 2011. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J. Immunol. 187: 2711-2722.
18. Duffield, J. S., M. Lupher, V. J. Thannickal, and T. A. Wynn. 2013. Host responses in tissue repair and fibrosis. Annu. Rev. Pathol. 8: 241-276.
19. Murray, P. J., and T. A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11: 723-737.
20. Wynn, T. A., and L. Barron. 2010. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 30: 245-257.
21. Angelini, D. J., Q. Su, K. Yamaji-Kegan, C. Fan, X. Teng, P. M. Hassoun, S. C. Yang, H. C. Champion, R. M. Tuder, and R. A. Johns. 2009. Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 41: 553-561.
22. Yamaji-Kegan, K., Q. Su, D. J. Angelini, A. C. Myers, C. Cheadle, and R. A. Johns. 2010. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) increases lung inflammation and activates pulmonary microvascular endothelial cells via an IL-4-dependent mechanism. J. Immunol. 185: 5539-5548.
23. Christmann, R. B., E. Hayes, S. Pendergrass, C. Padilla, G. Farina, A. J. Affandi, M. L. Whitfield, H. W. Farber, and R. Lafyatis. 2011. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum. 63: 1718-1728.
24. Vergadi, E., M. S. Chang, C. Lee, O. D. Liang, X. Liu, A. Fernandez-Gonzalez, S. A. Mitsialis, and S. Kourembanas. 2011. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation 123: 1986-1995.
25. Wynn, T. A. 2004. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4: 583-594.
26. Graham, B. B., J. Chabon, R. Kumar, E. Kolosionek, L. Gebreab, E. Debella, M. Edwards, K. Diener, T. Shade, G. Bifeng, et al. 2013. Protective role of IL-6 in vascular remodeling in Schistosoma pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 49: 951-959.
27. Knight, D. A., M. Ernst, G. P. Anderson, Y. P. Moodley, and S. E. Mutsaers. 2003. The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression? Pharmacol. Ther. 99: 327-338. (Pubitemid 37311198)
28. Natsume, M., H. Tsuji, A. Harada, M. Akiyama, T. Yano, H. Ishikura, I. Nakanishi, K. Matsushima, S. Kaneko, and N. Mukaida. 1999. Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride-treated IL-6-deficient mice. J. Leukoc. Biol. 66: 601-608. (Pubitemid 29489887)
29. Ash, Z., and P. Emery. 2012. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin. Biol. Ther. 12: 1277-1289.
30. Steiner,M. K., O. L. Syrkina, N. Kolliputi, E. J. Mark, C. A. Hales, and A. B. Waxman. 2009. Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104: 236-244, 28p following 244.
31. Soon, E., A. M. Holmes, C. M. Treacy, N. J. Doughty, L. Southgate, R. D. Machado, R. C. Trembath, S. Jennings, L. Barker, P. Nicklin, et al. 2010. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920-927.
32. Savale, L., L. Tu, D. Rideau, M. Izziki, B. Maitre, S. Adnot, and S. Eddahibi. 2009. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res. 10: 6.
33. Paulin, R., A. Courboulin, J. Meloche, V. Mainguy, E. Dumas de la Roque, N. Saksouk, J. Côté, S. Provencher, M. A. Sussman, and S. Bonnet. 2011. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 123: 1205-1215.
34. Paulin, R., J. Meloche, M. H. Jacob, M. Bisserier, A. Courboulin, and S. Bonnet. 2011. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 301: H1798-H1809.
35. Xue, J., S. V. Schmidt, J. Sander, A. Draffehn, W. Krebs, I. Quester, D. De Nardo, T. D. Gohel, M. Emde, L. Schmidleithner, et al. 2014. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40: 274-288.
36. Qualls, J. E., G. Neale, A. M. Smith, M. S. Koo, A. A. DeFreitas, H. Zhang, G. Kaplan, S. S. Watowich, and P. J. Murray. 2010. Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Sci. Signal. 3: ra62.
37. El Kasmi, K. C., J. Holst, M. Coffre, L. Mielke, A. de Pauw, N. Lhocine, A. M. Smith, R. Rutschman, D. Kaushal, Y. Shen, et al. 2006. General nature of the STAT3-activated anti-inflammatory response. J. Immunol. 177: 7880-7888. (Pubitemid 44846303)
38. Lang, R., A. L. Pauleau, E. Parganas, Y. Takahashi, J. Mages, J. N. Ihle, R. Rutschman, and P. J. Murray. 2003. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4: 546-550. (Pubitemid 36701337)
39. Fielding, C. A., G. W. Jones, R. M. McLoughlin, L. McLeod, V. J. Hammond, J. Uceda, A. S. Williams, M. Lambie, T. L. Foster, C. T. Liao, et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40: 40-50.
40. Humbert, M., G. Monti, F. Brenot, O. Sitbon, A. Portier, L. Grangeot-Keros, P. Duroux, P. Galanaud, G. Simonneau, and D. Emilie. 1995. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151: 1628-1631.
41. Yoshio, T., J. I. Masuyama, N. Kohda, D. Hirata, H. Sato, M. Iwamoto, A. Mimori, A. Takeda, S. Minota, and S. Kano. 1997. Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J. Rheumatol. 24: 489-495. (Pubitemid 27153413)
42. Ikezumi, Y., T. Suzuki, T. Karasawa, H. Hasegawa, T. Yamada, N. Imai, I. Narita, H. Kawachi, K. R. Polkinghorne, D. J. Nikolic-Paterson, and M. Uchiyama. 2011. Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology 58: 198-210.
43. Mathai, S. K., M. Gulati, X. Peng, T. R. Russell, A. C. Shaw, A. N. Rubinowitz, L. A. Murray, J. M. Siner, D. E. Antin-Ozerkis, R. R. Montgomery, et al. 2010. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab. Invest. 90: 812-823.
44. Weaver, L. K., P. A. Pioli, K. Wardwell, S. N. Vogel, and P. M. Guyre. 2007. Upregulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J. Leukoc. Biol. 81: 663-671. (Pubitemid 46393544)
45. Higashi-Kuwata, N., T. Makino, Y. Inoue, M. Takeya, and H. Ihn. 2009. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp. Dermatol. 18: 727-729.
46. Bacci, M., A. Capobianco, A. Monno, L. Cottone, F. Di Puppo, B. Camisa, M. Mariani, C. Brignole, M. Ponzoni, S. Ferrari, et al. 2009. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am. J. Pathol. 175: 547-556.
47. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35. (Pubitemid 37328697)
48. El Kasmi, K. C., J. E. Qualls, J. T. Pesce, A. M. Smith, R. W. Thompson, M. Henao-Tamayo, R. J. Basaraba, T. König, U. Schleicher, M. S. Koo, et al. 2008. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat. Immunol. 9: 1399-1406.
49. Gray, M. J., M. Poljakovic, D. Kepka-Lenhart, and S. M. Morris, Jr. 2005. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene 353: 98-106. (Pubitemid 40805364)
50. Dang, E. V., J. Barbi, H. Y. Yang, D. Jinasena, H. Yu, Y. Zheng, Z. Bordman, J. Fu, Y. Kim, H. R. Yen, et al. 2011. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146: 772-784.
51. Takeda, K., K. Noguchi, W. Shi, T. Tanaka, M. Matsumoto, N. Yoshida, T. Kishimoto, and S. Akira. 1997. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 94: 3801-3804. (Pubitemid 27180453)
52. Costa-Pereira, A. P., S. Tininini, B. Strobl, T. Alonzi, J. F. Schlaak, H. Is'harc, I. Gesualdo, S. J. Newman, I. M. Kerr, and V. Poli. 2002. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc. Natl. Acad. Sci. USA 99: 8043-8047. (Pubitemid 34651002)
53. Tuder, R. M., E. Stacher, J. Robinson, R. Kumar, and B. B. Graham. 2013. Pathology of pulmonary hypertension. Clin. Chest Med. 34: 639-650.
54. Nakayama, W., M. Jinnin, K. Makino, I. Kajihara, T. Makino, S. Fukushima, Y. Inoue, and H. Ihn. 2012. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol. Int. 32: 403-407.
55. Tantawy, A. A., A. A. Adly, and E. A. Ismail. 2012. Soluble CD163 in young sickle cell disease patients and their trait siblings: a biomarker for pulmonary hypertension and vaso-occlusive complications. Blood Coagul. Fibrinolysis 23: 640-648.
56. Campbell, L., C. R. Saville, P. J. Murray, S. M. Cruickshank, and M. J. Hardman. 2013. Local arginase 1 activity is required for cutaneous wound healing. J. Invest. Dermatol. 133: 2461-2470.
57. Jin, Y., T. J. Calvert, B. Chen, L. G. Chicoine, M. Joshi, J. A. Bauer, Y. Liu, and L. D. Nelin. 2010. Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am. J. Physiol. Heart Circ. Physiol. 298: H1518-H1528.
58. Barron, L., A. M. Smith, K. C. El Kasmi, J. E. Qualls, X. Huang, A. Cheever, L. A. Borthwick, M. S. Wilson, P. J. Murray, and T. A. Wynn. 2013. Role of arginase 1 from myeloid cells in th2-dominated lung inflammation. PLoS ONE 8: e61961.
59. Herbert, D. R., C. Hölscher, M. Mohrs, B. Arendse, A. Schwegmann, M. Radwanska, M. Leeto, R. Kirsch, P. Hall, H. Mossmann, et al. 2004. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 20: 623-635. (Pubitemid 38659504)
60. Herbert, D. R., T. Orekov, A. Roloson, M. Ilies, C. Perkins, W. O'Brien, S. Cederbaum, D. W. Christianson, N. Zimmermann, M. E. Rothenberg, and F. D. Finkelman. 2010. Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis. J. Immunol. 184: 6438-6446.
61. Voelkel, N. F., R. W. Vandivier, and R. M. Tuder. 2006. Vascular endothelial growth factor in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L209-L221.
62. Semenza, G. L. 2011. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 365: 537-547.
63. Jung, J. E., H. G. Lee, I. H. Cho, D. H. Chung, S. H. Yoon, Y. M. Yang, J. W. Lee, S. Choi, J. W. Park, S. K. Ye, and M. H. Chung. 2005. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 19: 1296-1298. (Pubitemid 41113728)
64. Xu, Q., J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G. L. Semenza, et al. 2005. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24: 5552-5560. (Pubitemid 43119350)
65. Paulin, R., J. Meloche, and S. Bonnet. 2012. STAT3 signaling in pulmonary arterial hypertension. JAK-STAT 1: 223-233.
66. Ramana, C. V., A. Kumar, and R. Enelow. 2005. Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Biochem. Biophys. Res. Commun. 327: 727-733. (Pubitemid 40092810)
67. Akira, S. 2000. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19: 2607-2611. (Pubitemid 30339216)
68. Pauleau, A. L., R. Rutschman, R. Lang, A. Pernis, S. S. Watowich, and P. J. Murray. 2004. Enhancer-mediated control of macrophage-specific arginase I expression. J. Immunol. 172: 7565-7573. (Pubitemid 38747620)
69. Rahman, S. M., R. C. Janssen, M. Choudhury, K. C. Baquero, R. M. Aikens, B. A. de la Houssaye, and J. E. Friedman. 2012. CCAAT/enhancer-binding protein β (C/EBPβ) expression regulates dietary-induced inflammation in macrophages and adipose tissue in mice. J. Biol. Chem. 287: 34349-34360.
70. Ruffell, D., F. Mourkioti, A. Gambardella, P. Kirstetter, R. G. Lopez, N. Rosenthal, and C. Nerlov. 2009. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl. Acad. Sci. USA 106: 17475-17480.
71. Huang, G. N., J. E. Thatcher, J. McAnally, Y. Kong, X. Qi, W. Tan, J. M. DiMaio, J. F. Amatruda, R. D. Gerard, J. A. Hill, et al. 2012. C/EBP transcription factors mediate epicardial activation during heart development and injury. Science 338: 1599-1603.